Bufalin Reverses HGF-Induced Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Cells via Blockage of Met/PI3k/Akt Pathway and Induction of Apoptosis

Figure 5

Bufalin combined with gefitinib overcomes resistance to gefitinib induced by HGF via activation of apoptosis signaling. (a) HCC827 cells were treated with gefitinib (1 μM) and/or bufalin (20 nM), in the presence of HGF (30 ng) for 24 h, and then stained with Annexin V/PI and detected by flow cytometry. (b) HCC827 cells were treated with gefitinib (1 μM) and/or bufalin (20 nM), in the presence of HGF (30 ng) for 24 h. Then cells were lyzed, and the associated proteins were detected by western blotting. Each bar represented mean ± SD. ^∗𝑃<0.05 and ^∗∗𝑃<0.01 compared with gefitinib, ^Δ𝑃<0.05 and ^ΔΔ𝑃<0.01 compared with bufalin.

(a)

(b)